Save

A Study to Evaluate Migalastat in Fabry Subjects with Amenable GLA Variant and Renal Disease

PHASE3RECRUITING

An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment (SRI) or End Stage Renal Disease (ESRD).

Simpliy with AI

Study details:

This is an open-label, non-comparative study for subjects with Fabry disease who have an estimated glomerular filtration rate (eGFR) based on the Modification of Diet in Renal Disease equation (eGFRMDRD) value of \< 30 mL/min/1. 73 m2. Subjects may have had previous exposure to migalastat, either commercially or as a participant in a previous migalastat study.

Two distinct populations of subjects with Fabry disease and renal impairment will be enrolled into this study:. * Cohort 1: Subjects with SRI not receiving any type of dialysis treatment. * Cohort 2: ESRD subjects who are receiving hemodialysis treatment, either standard hemodialysis (HD) or hemodiafiltration (HDF).

Only subjects who can receive HD/HDF at the study clinic or at an affiliated center where the Investigator already has oversight should be enrolled into Cohort 2. Subjects entering into this study will undergo screening (Visit 1) to confirm enrollment eligibility including confirmatory GLA genotyping. Subjects who meet eligibility criteria will have a Baseline Visit (Visit 2) within 30 days of screening.

Subjects who do not meet eligibility criteria (eg, subjects with an eGFR \> 30 mL/min/1. 73 m2) may be re-screened.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Male or female subjects aged 18 years or older, diagnosed with Fabry disease.

Subject (or legally authorized representative as applicable) is willing and able to provide written informed consent and authorization for use and disclosure of Personal Health Information

Subject has a GLA variant that is amenable to migalastat recorded in their medical records

Subject has at least 1 documented eGFR value of < 30 mL/min/1.73 m2 within the last 3 months and has an eGFRMDRD value of < 30 mL/min/1.73 m2 at Visit 1

Subjects with ESRD have been on a stable 2- or 3-times a week HD (standard or HDF) regimen for at least 2 months prior to the screening visit

Subjects with ESRD must commit to completing at least 4 standard HD or HDF sessions during each 2-week dosing interval.

Subjects with ESRD must commit to completing the entire prescribed duration for each dialysis session.

If of reproductive potential, both male and female patients agree to use a medically accepted method of contraception

Exclusion criteria

Subject has undergone kidney transplantation

Subject is on peritoneal dialysis

Subject is treated or has been treated with another investigational drug (except migalastat) within the 30 days

Subject has undergone any gene therapy at any time prior to the study or anticipates undergoing gene therapy during the study.

Subject has had a documented transient ischemic attack, stroke, unstable angina, or myocardial infarction

Subject has clinically significant unstable cardiac disease

Subject has any intercurrent illness or condition that may preclude the subject from fulfilling the protocol requirements

Subject has a history of allergy or sensitivity to migalastat (including excipients) or other iminosugars (eg, miglustat, miglitol)

Subject requires concurrent treatment with Glyset® (miglitol), Replagal® (agalsidase alfa), or Fabrazyme® (agalsidase beta)

Subject requires concurrent treatment with Zavesca® (miglustat) or has been treated with Zavesca

Female subject is pregnant or breast-feeding

Subject is unable to comply with study requirements

In France only, protected persons as defined by the Public Health Code

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2022-10-31

Primary completion: 2024-12-31

Study completion finish: 2025-12-31

Study type

TREATMENT

Phase

PHASE3

Trial ID

NCT04020055

Intervention or treatment

DRUG: migalastat HCl 150 mg

Conditions

• Fabry Disease

Condition: Fabry Disease
DRUG: migalastat HCl 150 mg
Parkville, Victoria, Australia and more
Sponsor: Amicus Therapeutics

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Royal Melbourne Hospital

Research sites nearby

Select from list below to view details:

Royal Melbourne Hospital
Parkville, Victoria, Australia
Royal Perth Hospital
Perth, Washington, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Cohort 1: Severe Renal Impairment All subjects will receive migalastat 123 mg, equivalent to 150 mg migalastat HCl (hereafter, migalastat) at a dose regimen based on their eGFRMDRD result at Visit 1. Subjects will take 1 migalastat capsule orally with water either every 4 or 7 days.	DRUG: migalastat HCl 150 mg migalastat HCl 150 mg capsule
EXPERIMENTAL: Cohort 2: End-Stage Renal Disease All hemodialysis subjects will receive migalastat 123 mg, equivalent to 150 mg migalastat HCl (hereafter, migalastat). Subjects will take 1 migalastat capsule orally with water every other week.	DRUG: migalastat HCl 150 mg migalastat HCl 150 mg capsule

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Maximum observed concentration (Cmax)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Time to maximum concentration (tmax)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Apparent terminal elimination half-life (t½)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK	Baseline through Month 12
Concentration at the end of a dosing interval at steady state (Ctrough)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Average plasma migalastat concentration over the dosing interval (Cavg)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Area under the concentration-time curve at steady state during the dosing interval (AUC0-τ)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Area under the concentration-time curve from zero time (pre-dose) extrapolated to infinite time (AUC0-∞)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Apparent plasma clearance (CL/F)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK	Baseline through Month 12
Apparent terminal phase volume of distribution (Vz/F)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Dialysis clearance (CLD)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Volume of dialysate collected during the interval (VD)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Mean migalastat concentration in dialysate (CD)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Amount recovered in dialysate (AeD)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Fraction of the dose recovered in dialysate (FeD)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Mean migalastat plasma concentration during the dialysis interval (P)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Mean inlet area under the curve (AUCinlet)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Mean outlet area under the curve (AUCoutlet)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Extraction ratio (ED)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Dialyzer blood flow (QD)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Cumulative amount excreted over all collection intervals (Ae0-τ)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Fraction of the dose recovered after the last measurable time point postdose (Fe0-τ)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12
Renal clearance (CLr)	To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.	Baseline through Month 12

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Adverse events (AEs)	To assess the safety and tolerability of migalastat in Fabry subjects with severe renal impairment and end stage renal disease.	Baseline through Month 12
Number of subjects with abnormal clinical chemistry laboratory test results	Blood samples will be collected for analysis of chemistry parameters.	Baseline through Month 12
Number of subjects with abnormal hematology laboratory test results	Blood samples will be collected for analysis of hematology parameters.	Baseline through Month 12
Number of subjects with abnormal urinalysis laboratory test results	Blood samples will be collected for analysis of urine parameters.	Baseline through Month 12
Number of subjects with abnormal electrocardiogram (ECG) findings as a measure of safety and tolerability	A 12-lead ECG will be obtained	Baseline through Month 12
Change from baseline in estimated glomerular filtration rate (eGFR) based on the Modification of Diet in Renal Disease equation (eGFR MDRD)	To assess the safety and tolerability of migalastat in Fabry subjects with severe renal impairment and end stage renal disease	Baseline through Month 12
Change from baseline eGFR based on the Chronic Kidney Disease Epidemiology Collaboration equation (eGFRCKD-EPI)	To assess the safety and tolerability of migalastat in Fabry subjects with severe renal impairment and end stage renal disease	Baseline through Month 12
Change from baseline in plasma globotriaosylsphingosine (lyso-Gb3)	To evaluate the pharmacodynamics (PD) of migalastat in subjects with Fabry disease and severe renal impairment	Baseline through Month 12

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: A Study to Evaluate Migalastat in Fabry Subjects with Amenable GLA Variant and Renal Disease